TBGNF News Alert Thromboogenics Nv (TBGNF) 9.6000 09/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Thromboogenics Nv (TBGNF) 9.6000 $TBGNF

ThromboGenics Plays Long Game for Eye Disease
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
ThromboGenics NV recently announced that it received a 3 million euro grant from the Flemish agency for Innovation by Science and Technology to support development of new therapeutics for diabetic macular edema. The new program will complement...

ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
PR Newswire Europe - Thu Sep 05, 12:31AM CDT
LEUVEN, Belgium, September 5, 2013 /PRNewswire/ --

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Acute Ischemic Stroke - Pipeline Review, H2 2013 Report Assists you in Identifying Players of the Most Promising Pipeline
M2 - Mon Sep 02, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/jcs2gq/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke. Acute Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Ischemic Stroke. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - D-Pharm Ltd. - Daiichi Sankyo Company, Ltd - FCB-Pharmicell Co.,Ltd. - Gaia BioPharma Limited - Glucox Biotech - H Lundbeck A/S - M's Science Corporation - Manipal AcuNova Ltd - Mitsubishi Tanabe Pharma Corporation - Oxygen Biotherapeutics, Inc. - PhytoHealth Corporation - Reliance Life Sciences Pvt. Ltd. - Remedy Pharmaceuticals, Inc. - Sanofi-Aventis - Stem Cell Therapeutics Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/jc...e_ischemic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion
PR Newswire - Fri Aug 16, 9:13AM CDT
Canada is first market outside the US and Europe where JETREA® is approved

Germany's IQWiG Confirms That ThromboGenics' JETREA(R) Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire Europe - Fri Aug 02, 12:31AM CDT
LEUVEN, Belgium, August 2, 2013 /PRNewswire/ --

Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire - Fri Aug 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA® (ocriplasmin) demonstrates major / significant added value in VMT patients with mild / moderately severe symptoms compared with existing comparative treatment, when treating vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns.

ThromboGenics' JETREA(R) Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire Europe - Wed Jun 12, 12:01AM CDT
LEUVEN, Belgium, June 12, 2013 /PRNewswire/ --

ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire - Wed Jun 12, 12:00AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has provisionally recommended JETREA® (ocriplasmin) for reimbursement within the National Health Service (NHS). The NICE Appraisal Consultation Document (ACD) initially recommends JETREA® as an option for treating vitreomacular traction (VMT) in adults, including when associated with a macular hole of less than or equal to 400 microns, when patients have severe symptoms and an epiretinal membrane is not present.

ThromboGenics Licenses Innovative Technology from Eleven Biotherapeutics to Develop Novel Drugs for the Treatment of Diabetic Eye Diseases
PR Newswire Europe - Tue May 28, 11:03AM CDT
LEUVEN, Belgium, May 28, 2013 /PRNewswire/ --

Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease
Business Wire - Tue May 28, 10:45AM CDT
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that they have entered into a research collaboration and license agreement with ThromboGenics NV to research and develop a protein therapeutic based on a novel biologic target implicated in ophthalmic disease. The collaboration aims to employ Eleven's proprietary AMP-Rx protein design technology to optimize a novel therapeutic of ThromboGenics' selection to have improved pharmaceutical characteristics and therapeutic benefits. The novel biologic will be designed to treat back of the eye diseases such as diabetic macular edema.

ThromboGenics' JETREA® Launched in Denmark and Sweden
PR Newswire - Mon May 27, 10:45AM CDT
Roll out in Finland and Norway to follow shortly

ThromboGenics Business Update
PR Newswire Europe - Thu May 16, 11:16AM CDT
LEUVEN, Belgium, May 16, 2013 /PRNewswire/ --

ThromboGenics' JETREA(R) Available in Germany Public and Private Market
PR Newswire Europe - Thu May 02, 12:31AM CDT
LEUVEN, Belgium, May 2, 2013 /PRNewswire/ --

ThromboGenics' JETREA® Available in Germany Public and Private Market
PR Newswire - Thu May 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available.

Thrombocytopenia - Pipeline Review, H1 2013
M2 - Wed Apr 24, 5:49AM CDT
Research and Markets has announced the addition of the Thrombocytopenia - Pipeline Review, H1 2013 report to their offering. 'Thrombocytopenia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. Scope - A snapshot of the global therapeutic scenario for Thrombocytopenia. - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocytopenia pipeline on the basis

ThromboGenics' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, now Launched in the UK
PR Newswire - Thu Apr 11, 10:45AM CDT
First EU JETREA® order triggers EUR45 million milestone payment from Alcon to ThromboGenics

ThromboGenics Starts Trading as Part of the BEL20 Index Today
PR Newswire Europe - Mon Mar 18, 1:31AM CDT
LEUVEN, Belgium, March 18, 2013 /PRNewswire/ --




Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 112

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 97

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 202

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 55

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 204

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 97

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 173

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 97

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading

Top 5 Most Recently Viewed Articles

Pivot Point Consulting Triumphs as KLAS Leader for IT Services

Updated Category News Views 146

Pivot Point Consulting Recognized as a Leader in Managed IT Services For three consecutive years, Pivot Point Consulting has earned the prestigious title of #1 Best in KLAS: Managed IT Services. This recognition, based on outstanding client feedback, highlights their ongoing commitment to excellence in the healthcare IT sector. The Significance of KLAS Rankings KLAS...

Continue Reading
Revolutionizing Intelligent Vision: Leopard Imaging's New Offerings

Updated Category News Views 203

Revolutionizing Intelligent Vision Solutions Leopard Imaging Inc., a pioneering company in intelligent vision technology, has unveiled its groundbreaking high-resolution RGB-IR stereo camera series, known as Eagle. This series is powered by two of the most advanced technologies from NVIDIA: Holoscan and Jetson Thor. As a leading innovator in the realm of intelligent...

Continue Reading
Gartner's CEO Eugene Hall Executes Major Stock Sales

Updated Category News Views 320

Eugene Hall's Major Stock Sales at Gartner Gartner Inc. (NYSE: IT) is in the spotlight following a significant stock sale by its Chairman and CEO, Eugene A. Hall. This recent move, detailed in an SEC filing, shows that Hall sold shares worth a considerable total of $17,213,808. Overview of Hall's Stock Transactions Hall's stock sales occurred over several transactions,...

Continue Reading
How Canadian Tariffs Could Impact These 5 Companies

Updated Category News Views 1409

Understanding the Potential Impact of Canadian Tariffs The announcement of possible tariffs on Canadian imports has taken many businesses by surprise, igniting a wave of concern across multiple sectors. Companies are now racing to reassess their strategies as new cost structures could potentially shape their futures. What Does This Mean for U.S. Companies? The initiative...

Continue Reading
Holley Performance Brands Launches Major Stock Offering

Updated Category News Views 309

Holley Performance Brands Unveils Secondary Stock Offering Holley Performance Brands (NYSE: HLLY) has recently made headlines by announcing a secondary offering of its common stock, which aims to raise capital and create further investment opportunities for investors. This move underscores Holley's commitment to enhancing its presence in the automotive performance market....

Continue Reading